Lilly's lebrikizumab, delayed at FDA, clears eczema in people with skin of color

Eli Lilly’s eczema medicine lebrikizumab cleared skin and provided itch relief in a study that was specifically designed for people with skin of color.

The phase 3 results, presented at the American Academy of Dermatology Annual Meeting over the weekend, matched previous data from a previous late-stage study of the IL-13-targeting monoclonal antibody, Lilly said in a Sunday press release.